Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1960 2
1961 1
1962 1
1966 2
1968 2
1969 1
1970 2
1971 2
1972 2
1973 2
1974 1
1975 1
1978 1
1980 4
1981 2
1986 2
1987 1
1988 1
1989 6
1990 6
1991 2
1992 6
1993 5
1994 1
1995 6
1996 6
1997 4
1998 3
1999 5
2000 7
2001 11
2002 11
2003 9
2004 17
2005 22
2006 25
2007 20
2008 19
2009 20
2010 28
2011 24
2012 30
2013 30
2014 27
2015 30
2016 23
2017 25
2018 28
2019 30
2020 26
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

507 results
Results by year
Filters applied: . Clear all
Page 1
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Herbst RS, et al. Among authors: gordon ms. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. Nature. 2014. PMID: 25428504 Free PMC article. Clinical Trial.
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Corcoran RB, et al. Among authors: gordon ms. Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431699 Free PMC article. Clinical Trial.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Emens LA, et al. Among authors: gordon ms. JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. JAMA Oncol. 2019. PMID: 30242306 Free PMC article. Clinical Trial.
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Massard C, et al. Among authors: gordon ms. J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269937 Free PMC article. Clinical Trial.
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial.
Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Jameson GS, et al. Among authors: gordon ms. JAMA Oncol. 2019 Oct 3;6(1):125-32. doi: 10.1001/jamaoncol.2019.3394. Online ahead of print. JAMA Oncol. 2019. PMID: 31580386 Free PMC article.
Many-Body Dispersion.
Xu P, Alkan M, Gordon MS. Xu P, et al. Among authors: gordon ms. Chem Rev. 2020 Nov 25;120(22):12343-12356. doi: 10.1021/acs.chemrev.0c00216. Epub 2020 Nov 9. Chem Rev. 2020. PMID: 33166127
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. Gerber DE, et al. Among authors: gordon ms. Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20. Clin Cancer Res. 2020. PMID: 31540980 Free article. Clinical Trial.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Infante JR, et al. Among authors: gordon ms. Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16. Lancet Oncol. 2012. PMID: 22805291 Clinical Trial.
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. Middleton G, et al. Among authors: gordon ms. Clin Cancer Res. 2020 Jun 1;26(11):2466-2476. doi: 10.1158/1078-0432.CCR-19-3579. Epub 2020 Feb 11. Clin Cancer Res. 2020. PMID: 32047001 Free article.
507 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page